Skip to main content
SpringerLink
Log in

Gonadotrophin-Releasing Hormone Agonists

A Guide to Use and Selection

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 01 August 1994

Summary

The development of superactive analogues of gonadatrophin-releasing hormone (GnRH) represents one of the most important new pharmaceutical contributions of the last 2 decades. This class of drugs is now available worldwide and is successfully employed in the management of precocious puberty, ovulation induction, prostatic cancer, premenopausal breast cancer, endometriosis, uterine leiomyoma, and for the preparation of female patients undergoing laparotomic, vaginal or endoscopic surgery. GnRH agonists are also applied with some success in other clinical conditions such as catamenial disorders, hyperandrogenism and menometrorrhagia. Studies are under way to identify other potential clinical applications such as other forms of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fujino M, Kobayashi S, Obayashi M, et al. Structure-activity relationships in the C-terminal part of luteinising hormone releasing hormone (LH-RH). Biochem Biophys Res Commun 1972; 49: 863–7

    Article  PubMed  CAS  Google Scholar 

  2. Monahan MW, Amoss MS, Anderson HA, et al. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry 1973; 12: 4616–9

    Article  PubMed  CAS  Google Scholar 

  3. Nestor Jr JJ, Ho TL, Simpson RA, et al. Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone releasing hormone. J Med Chem 1982; 25: 795–800

    Article  PubMed  CAS  Google Scholar 

  4. Dutta AS, Furr BJA, Giles MB, et al. Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10. Biochem Biophys Res Commun 1978; 81: 382–5

    Article  PubMed  CAS  Google Scholar 

  5. Ling N, Vale W. Analog of luteinizing hormone releasing factor (LRF): synthesis and biological activity of [(N-Me)Leu7]LRF and [D-Ala6, N-Me)-Leu7] LRF. Biochem Biophys Res Commun 1975; 63: 801–6

    Article  PubMed  CAS  Google Scholar 

  6. Nestor JJ. Design of LHRH agonist drug candidates. J Androl 1987; 8: S4–S8

    PubMed  CAS  Google Scholar 

  7. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design: structure-function studies toward the development of agonists and antagonists: Rationale and perspective. Endocr Rev 1986; 7: 44–63

    Article  PubMed  CAS  Google Scholar 

  8. Coy DH, Vilchez-Martinez JA, Coy EJ, et al. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem 1976; 19: 423–5

    Article  PubMed  CAS  Google Scholar 

  9. Benuck M, Marks N. Differences in the degradation of hypothalamic releasing factors by rat and human serum. Life Sci 1976; 19: 1271–6

    Article  PubMed  CAS  Google Scholar 

  10. Pavlou SN. The mechanism of action of GnRH agonists. Infert Reprod Med Clin North Am 1993; 4: 9–19

    Google Scholar 

  11. Janaky T, Juhasz A, Bajusz S, et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci USA 1992; 89: 972–6

    Article  PubMed  CAS  Google Scholar 

  12. Holland FJ, Fishman L, Castigan DC, et al. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10 lutenizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin Endocrinol Metab 1986; 63: 1065–70

    Article  PubMed  CAS  Google Scholar 

  13. Fraser HM, Sandow J, Seidel H, et al. An implant of a gonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3–5 months. Acta Endocrinol (Copenh) 1987; 115: 521–7

    CAS  Google Scholar 

  14. Perren TJ, Clayton RN, Blackledge G, et al. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother Pharmacol 1986; 18: 39–43

    Article  PubMed  CAS  Google Scholar 

  15. Shimamoto T. Pharmaceutical aspects. Nasal and depot formulations of leuprolide. J Androl 1987; 8: S14–S16

    PubMed  CAS  Google Scholar 

  16. Filicori M, Flamigni C, Cognigni G, et al. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 1993; 77: 130–3

    Article  PubMed  CAS  Google Scholar 

  17. Reichel PR, Schweppe KW. Goserelin (Zoladex*) depot in the treatment of endometriosis. Fertil Steril 1992; 57: 1197–202

    PubMed  CAS  Google Scholar 

  18. Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate depot treatment. Fertil Steril 1993; 59: 448–50

    PubMed  CAS  Google Scholar 

  19. Friedman AJ, Daly M, Juneau-Norcross M, et al. A prospective, randomised trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ‘add-back’ regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993; 76: 1439–45

    Article  PubMed  CAS  Google Scholar 

  20. Maheux R, Lemay A, Blanchet P, et al. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 1991; 6: 500–5

    PubMed  CAS  Google Scholar 

  21. Carmina E, Janni A, Lobo R. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. J Clin Endocrinol Metab 1994; 78: 126–30

    Article  PubMed  CAS  Google Scholar 

  22. Filicori M, Flamigni C. GnRH agonists and antagonists: a review of their current status. Drugs 1988; 35: 63–82

    Article  PubMed  CAS  Google Scholar 

  23. Boepple PA, Frisch LS, Wierman ME, et al. The natural history of autonomous gonadal function, adrenarche, and central puberty in gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 1992; 75: 1550–5

    Article  PubMed  CAS  Google Scholar 

  24. Mansfield MJ, Rudlin CR, Crigler JF, et al. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab 1988; 66: 3–9

    Article  PubMed  CAS  Google Scholar 

  25. DiMartino-Nardi J, Wu R, Fishman K, et al. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty. J Clin Endocrinol Metab 1991; 73: 902–6

    Article  PubMed  CAS  Google Scholar 

  26. Sklar CA, Rothenberg S, Blumberg D, et al. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion. J Clin Endocrinol Metab 1991; 73: 734–8

    Article  PubMed  CAS  Google Scholar 

  27. Berga SL, Jones KL, Kaufmann S, et al. Nocturnal melatonin levels are unaltered by ovarian suppression in girls with central precocious puberty. Fertil Steril 1989; 52: 936–41

    PubMed  CAS  Google Scholar 

  28. Pescovitz OH, Barnes KM, Cutler Jr GB. Effect of deslorelin dose in the treatment of central precocious puberty. J Clin Endocrinol Metab 1991; 72: 60–4

    Article  PubMed  CAS  Google Scholar 

  29. Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 1991; 73: 50–2

    Article  PubMed  CAS  Google Scholar 

  30. Laue L, Jones J, Barnes KM, et al. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993; 76: 151–5

    Article  PubMed  CAS  Google Scholar 

  31. Kreiter M, Burstein S, Rosenfield RL, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 1990; 117: 364–70

    Article  PubMed  CAS  Google Scholar 

  32. Oostdijk W, Gevers EF, Drop SL, et al. Growth and pubertal development during and after treatment with a slow-release gonadotropin-releasing hormone agonist in central precocious puberty. Horm Res 1991; 36: 121–5

    Article  PubMed  CAS  Google Scholar 

  33. Oerter KE, Manasco P, Barnes KM, et al. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab 1991; 73: 1235–40

    Article  PubMed  CAS  Google Scholar 

  34. Cara JF, Kreiter ML, Rosenfield RL. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone. J Pediatr 1992; 120: 709–15

    Article  PubMed  CAS  Google Scholar 

  35. Municchi G, Rose SR, Pescovitz OH, et al. Effect of deslorelin-induced pubertal delay on the growth of adolescents with short stature and normally timed puberty: preliminary results. Fertil Steril 1993; 77: 1334–9

    CAS  Google Scholar 

  36. Jay N, Mansfield MJ, Blizzard RM, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992; 75: 890–4

    Article  PubMed  CAS  Google Scholar 

  37. Filicori M, Flamigni C, Meriggiola MC, et al. Ovulation induction with pulsatile gonadotropin-releasing hormone: technical modalities and clinical perspectives. Fertil Steril 1991; 56: 1–13

    PubMed  CAS  Google Scholar 

  38. Filicori M, Campaniello E, Michelacci L, et al. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH. J Clin Endocrinol Metab 1988; 66: 327–33

    Article  PubMed  CAS  Google Scholar 

  39. Filicori M, Flamigni C, Campaniello E, et al. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management. J Clin Endocrinol Metab 1989; 69: 825–31

    Article  PubMed  CAS  Google Scholar 

  40. Filicori M, Flamigni C, Meriggiola MC, et al. Endocrine response determines the clinical outcome of pulsatile GnRH ovulation induction in different ovulatory disorders. J Clin Endocrinol Metab 1991; 72: 965–72

    Article  PubMed  CAS  Google Scholar 

  41. Filicori M, Flamigni C, Dellai P, et al. Treatment of anovulation with pulsatile GnRH: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab. In press

  42. Dodson WC, Hughes CL, Whitesides DB, et al. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1987; 65: 95–100

    Article  PubMed  CAS  Google Scholar 

  43. Filicori M, Cognigni G, Arnone R, et al. GnRH agonist (GnRHA)-induced endocrine changes markedly affect folliculogene-sis independently of exogenous gonadotropins (gn). Proceedings of the 76th Annual Meeting of the Endocrine Society; 1994 June 15–18: Anaheim. Anaheim: The Endocrine Society, 1994. In press

  44. Tan SL, Kingsland C, Campbell S, et al. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril 1992; 57: 810–4

    PubMed  CAS  Google Scholar 

  45. Louvet JP, Harman SM, Schreiber JR, et al. Evidence for a role of androgens in follicular maturation. Endocrinology 1975; 97: 366–72

    Article  PubMed  CAS  Google Scholar 

  46. Lefevre B, Gougeon A, Nome F, et al. Effect of a gonadotropin-releasing hormone agonist and gonadotropins on ovarian follicles in cynomolgus monkey: a model for human ovarian hyperstimulation. Fertil Steril 1991; 56: 119–25

    PubMed  CAS  Google Scholar 

  47. Cedars ML, Surey E, Hamilton F, et al. Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval. Fertil Steril 1990; 53: 627–31

    PubMed  CAS  Google Scholar 

  48. Dor J, Shulman A, Pariente C, et al. The effect of gonadotropin-releasing hormone agonist on the ovarian response and in vitro fertilization results in polycystic ovarian syndrome: a prospective study. Fertil Steril 1992; 57: 366–71

    PubMed  CAS  Google Scholar 

  49. Tummon IS, Daniel SA, Kaplan BR, et al. Randomised, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro fertilization. Fertil Steril 1992; 58: 563–8

    PubMed  CAS  Google Scholar 

  50. Chetkowski RJ, Rode RA, Burruel V, et al. The effect of pituitary suppression and the women’s age on embryo viability and uterine receptivity. Fertil Steril 1991; 56: 1095–103

    PubMed  CAS  Google Scholar 

  51. Chetkowski RJ, Kruse LR, Nass TE. Improved pregnancy outcome with the addition of leuprolide acetate to gonadotropins for in vitro fertilization. Fertil Steril 1989; 52: 250–5

    PubMed  CAS  Google Scholar 

  52. Abdalla HI, Ahuja KK, Leonard T, et al. Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril 1990; 53: 473–8

    PubMed  CAS  Google Scholar 

  53. Poison DW, MacLachlan V, Krapez JA, et al. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate*) for folliculogenesis in routine in vitro fertilization patients. Fertil Steril 1991; 56: 509–14

    Google Scholar 

  54. Hughes EG, Fedorkow DM, Daya S, et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomised controlled trials. Fertil Steril 1992; 58: 888–96

    PubMed  CAS  Google Scholar 

  55. Kingsland C, Tan SL, Bickerton N, et al. The routine use of gonadotropin-releasing hormone agonists for all patients undergoing in vitro fertilization: is there any medical advantage? A prospective randomised study. Fertil Steril 1992; 57: 804–9

    PubMed  CAS  Google Scholar 

  56. Palermo R, Amodeo G, Navot D, et al. Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles. Fertil Steril 1988; 49: 290–5

    PubMed  CAS  Google Scholar 

  57. McLachlan V, Besanko M, o’shea F, et al. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization. N Engl J Med 1989; 320: 1233–7

    Article  Google Scholar 

  58. Dodson WC, Hughes CL, Yancy SE, et al. Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. Fertil Steril 1989; 52: 915–8

    PubMed  CAS  Google Scholar 

  59. Surrey ES, Cedars MI. The effect of a gonadotropin suppression on the induction of ovulation in premature ovarian failure patients. Fertil Steril 1989; 52: 36–41

    PubMed  CAS  Google Scholar 

  60. Loumaye E, Vankrieken L, Depreester S, et al. Hormonal changes induced by short-term administration of a gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertil Steril 1989; 51: 105–11

    PubMed  CAS  Google Scholar 

  61. San Roman GA, Surrey ES, Judd HL, et al. A prospective randomised comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1992; 58: 744–9

    PubMed  CAS  Google Scholar 

  62. Garcia JE, Padilla SL, Bayati J, et al. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril 1990; 53: 302–5

    PubMed  CAS  Google Scholar 

  63. Frydman R, Belaisch-Allart J, Parneix I, et al. Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program. Fertil Steril 1988; 50: 471–5

    PubMed  CAS  Google Scholar 

  64. Acharya U, Small J, Randall J, et al. Prospective study of short and long regimens of gonadotropin-releasing hormone agonist in in vitro fertilization program. Fertil Steril 1992; 57: 815–8

    PubMed  CAS  Google Scholar 

  65. Jacobson A, Galen D, Milani H, et al. A novel superovulation regimen: three-day gonadotropin-releasing hormone agonist with overlapping gonadotropins. Fertil Steril 1991; 56: 1169–72

    PubMed  CAS  Google Scholar 

  66. Ron-El R, Herman A, Golan A, et al. Ultrashort gonadotropin-releasing hormone agonist (GnRHA) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone. Fertil Steril 1992; 58: 1164–8

    PubMed  CAS  Google Scholar 

  67. Tulchinsky D, Nash H, Brown K, et al. A pilot study of the use of gonadotropin-releasing hormone analog for triggering ovulation. Fertil Steril 1991; 55: 644–6

    PubMed  CAS  Google Scholar 

  68. Corson SL, Batzer FR, Gocial B, et al. The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist. Fertil Steril 1993; 59: 1251–6

    PubMed  CAS  Google Scholar 

  69. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod 1992; 7: 320–7

    PubMed  CAS  Google Scholar 

  70. Tejada MI, Mendoza R, Corcostegui B, et al. Chromosome studies in human unfertilized oocytes and uncleaved zygotes after treatment with gonadotropin-releasing hormone analogs. Fertil Steril 1991; 56: 874–80

    PubMed  CAS  Google Scholar 

  71. Oehninger S, Toner JP, Veeck LL. Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with or without a gonadotropin-releasing hormone agonist. Fertil Steril 1992; 57: 620–5

    PubMed  CAS  Google Scholar 

  72. Dicker D, Goldman JA, Levy T, et al. The impact of long-term gonadotropin-releasing hormone analogue treatment on preclinical abortions in patients with severe endometriosis undergoing in vitro fertilization-embryo transfer. Fertil Steril 1992; 57: 597–600

    PubMed  CAS  Google Scholar 

  73. Kang IS, Kuehl TJ, Siler-Khodr TM. Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril 1989; 52: 846–53

    PubMed  CAS  Google Scholar 

  74. Ghazi DM, Kemmann E, Hammond JM. Normal pregnancy outcome after early maternal exposure to gonadotropin releasing hormone agonist: a case report. J Reprod Med 1991; 36: 173–4

    PubMed  CAS  Google Scholar 

  75. Porcu E, Filicori M, Dal Prato L, et al. Comparison between depot leuprorelin and daily buserelin in IVF. Proceedings of the 50th Annual Meeting of the American Fertility Society; 1994 Nov 5–10: San Antonio, Texas. San Antonio: American Fertility Society. In press

  76. Filicori M, Hall DA, Loughlin JS, et al. Aconservative approach to the management of uterine leiomyoma: pituitary desensitisation by an LHRH analogue. Am J Obstet Gynecol 1983; 147: 726–7

    PubMed  CAS  Google Scholar 

  77. Vollenhoven BJ, Shekleton P, McDonald J, et al. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women. Fertil Steril 1990; 54: 1032–8

    PubMed  CAS  Google Scholar 

  78. Watanabe Y, Nakamura GI, Matsuguchi H, et al. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril 1992; 58: 66–71

    PubMed  CAS  Google Scholar 

  79. Friedman AJ, Harrison-Atlas D, Barbieri RL, et al. A randomised, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril 1989; 51: 251–6

    PubMed  CAS  Google Scholar 

  80. Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicentre study. The Leuprolide Study Group. Obstet Gynecol 1991; 77: 720–5

    CAS  Google Scholar 

  81. Fedele L, Vercellini P, Bianchi S, et al. Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol 1990; 97: 393–6

    Article  PubMed  CAS  Google Scholar 

  82. Friedman AJ, Daly M, Juneau-Norcross M, et al. Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril 1992; 58: 205–8

    PubMed  CAS  Google Scholar 

  83. Andreyko JL, Blumenfeld Z, Marshall LA, et al. Use of an agonist analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988; 158: 903–10

    PubMed  CAS  Google Scholar 

  84. Zawin M, McCarthy S, Scoutt L, et al. Monitoring therapy with a gonadotropin-releasing hormone analog: utility of MR imaging. Radiology 1990; 175: 503–6

    PubMed  CAS  Google Scholar 

  85. Lubich LM, Alderman MG, Ros PR. Magnetic resonance imaging of leiomyomata uteri: assessing therapy with the gonadotropin-releasing hormone agonist leuprolide. Magn Reson Imaging 1991; 9: 331–4

    Article  PubMed  CAS  Google Scholar 

  86. Wiznitzer A, Marbach M, Hazum E, et al. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 1988; 152: 1326–31

    Article  PubMed  CAS  Google Scholar 

  87. Friedman AJ, Daly M, Juneau-Norcross M, et al. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing agonist. Fertil Steril 1992; 58: 413–5

    PubMed  CAS  Google Scholar 

  88. Barbieri RL, Dilena M, Chumas J, et al. Leuprolide acetate depot decreases the number of nucleolar organiser regions in uterine leiomyomata. Fertil Steril 1993; 60: 569–70

    PubMed  CAS  Google Scholar 

  89. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol 1993; 24: 1073–7

    Article  PubMed  CAS  Google Scholar 

  90. Ellennbogen A, Shulman A, Libail Y, et al. Complications of triptorelin treatment for uterine myomas. Lancet 1989; 2: 167–8

    Article  Google Scholar 

  91. Lee MJ, Kazer RR. Massive ascites after leuprolide acetate administration for the treatment of leiomyomata uteri. Fertil Steril 1992; 58: 416–8

    PubMed  CAS  Google Scholar 

  92. Meyer WR, Diamond MP, Carcangiu ML, et al. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990; 75: 529–32

    PubMed  CAS  Google Scholar 

  93. Loong EPL, Wong FWS. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid. Fertil Steril 1990; 54: 530–1

    PubMed  CAS  Google Scholar 

  94. Hitti IF, Glasberg SS, McKenzie C, et al. Uterine leiomyosarcoma with massive necrosis diagnosed during gonadotropin-releasing hormone analog therapy for presumed uterine fibroid. Fertil Steril 1991; 56: 778–80

    PubMed  CAS  Google Scholar 

  95. Friedman AJ, Barbieri RL, Doubilet PM, et al. A randomised, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404–9

    PubMed  CAS  Google Scholar 

  96. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomised, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76: 1217–23

    Article  PubMed  CAS  Google Scholar 

  97. Lumsden MA, West CP, Baird DT. Goserelin therapy before surgery for uterine fibroids. Lancet 1987; 1: 36–7

    Article  PubMed  CAS  Google Scholar 

  98. Friedman AJ, Rein MS, Harrison-Atlas D, et al. A randomised, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 1989; 52: 728–33

    PubMed  CAS  Google Scholar 

  99. Schneider D, Golan A, Bukovsky I, et al. GnRH analogue-induced uterine shrinkage enabling a vaginal hysterectomy and repair in large leiomyomatous uteri. Obstet Gynecol 1991; 78: 540–1

    PubMed  CAS  Google Scholar 

  100. Stovall TG, Ling FW, Henry LC, et al. A randomised trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420–3

    PubMed  CAS  Google Scholar 

  101. Donnez J, Schrurs B, Gillerot S, et al. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989; 51: 947–50

    PubMed  CAS  Google Scholar 

  102. Donnez J, Gillerot S, Bourgonjon D, et al. Neodymium: YAG laser hysteroscopy in large submucous fibroids. Fertil Steril 1990; 54: 999–1003

    PubMed  CAS  Google Scholar 

  103. Dubuisson JB, Lecuru F, Foulot H, et al. Gonadotrophin-releasing hormone agonist and laparoscopic myomectomy. Clin Ther 1992; 14 Suppl. A: 51–6

    PubMed  Google Scholar 

  104. Kettel LM, Murphy AA, Morales AJ, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 1993; 60: 642–6

    PubMed  CAS  Google Scholar 

  105. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76: 513–7

    Article  PubMed  CAS  Google Scholar 

  106. Meldrum DR, Chang RJ, Lu J, et al. ‘Medical oophorectomy’ using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 1982; 54: 1081–3

    Article  PubMed  CAS  Google Scholar 

  107. Grow DR, Filer RB. Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol 1991; 78: 538–9

    PubMed  CAS  Google Scholar 

  108. Nelson JR, Corson SL. Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report. Fertil Steril 1993; 59: 441–3

    PubMed  CAS  Google Scholar 

  109. Hellberg D, Fors B, Bergqvist C. Renal endometriosis treated with a gonadotrophin releasing hormone agonist. Case report. Br J Obstet Gynaecol 1991; 98: 406–7

    Article  PubMed  CAS  Google Scholar 

  110. Espaulella J, Armengol J, Bella F, et al. Pulmonary endometriosis: conservative treatment with GnRH agonists. Obstet Gynecol 1991; 78: 535–7

    PubMed  CAS  Google Scholar 

  111. Yu J, Grimes DA. Ascites and pleural effusions associated with endometriosis. Obstet Gynecol 1991; 78: 533–4

    PubMed  CAS  Google Scholar 

  112. Hickok LR, Burry KA, Cohen NL, et al. Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones. Fertil Steril 1991; 56: 622–7

    PubMed  CAS  Google Scholar 

  113. Surrey ES, Halme J. Direct effects of medroxyprogesterone acetate, danazol, and leuprolide acetate on endometrial stromal cell proliferation in vitro. Fertil Steril 1992; 58: 273–8

    PubMed  CAS  Google Scholar 

  114. Fedele L, Marchini M, Bianchi S, et al. Endometrial patterns during danazol and buserelin therapy for endometriosis: comparative structural and ultrastructural study. Obstet Gynecol 1990; 76: 79–84

    PubMed  CAS  Google Scholar 

  115. Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 1988; 318: 485–9

    Article  PubMed  CAS  Google Scholar 

  116. Lemay A, Brideau NA, Forest JC, et al. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol. Clin Endocrinol 1991; 35: 305–10

    Article  CAS  Google Scholar 

  117. Franssen AM, van der Heijden PF, Thomas CM, et al. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Fertil Steril 1992; 57: 974–9

    PubMed  CAS  Google Scholar 

  118. Kiesel L, Thamas K, Tempone A. Efficacy and safety of buserelin treatment in women with endometriosis: a multi-centre open-lable study. Gynecol Endocrinol 1989; 3 Suppl. 2:5–19

    Google Scholar 

  119. Shaw RW, Zoladex Endometriosis Study Team. An open randomised comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992; 58: 265–72

    PubMed  CAS  Google Scholar 

  120. The Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil Steril 1992; 57: 514–22

    Google Scholar 

  121. Cedars M, Lu JKH, Meldrum DR, et al. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 1990; 75: 641–5

    PubMed  CAS  Google Scholar 

  122. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomised trial. J Clin Endocrinol Metab 1992; 75: 558–63

    Article  PubMed  CAS  Google Scholar 

  123. Santen RJ. Clinical Review 37: Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992; 75: 685–9

    Article  PubMed  CAS  Google Scholar 

  124. Labrie F, Belanger A, Simard J, et al. Combination therapy for prostate cancer: endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 1993; 71 Suppl. 3: 1059–67

    Article  PubMed  CAS  Google Scholar 

  125. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24

    Article  PubMed  CAS  Google Scholar 

  126. Crawford ED, Nabors W. Hormone therapy of advanced prostate cancer: where we stand today. Oncology 1991; 5: 21–8

    PubMed  CAS  Google Scholar 

  127. Crawford ED, Nabors WL. Total androgen ablation: American experience. Urol Clin North Am 1991; 18: 55–63

    PubMed  CAS  Google Scholar 

  128. Denis L. Prostate cancer: primary hormonal treatment. Cancer 1993; 71: 1050–8

    Article  PubMed  CAS  Google Scholar 

  129. Rutqvist LE, Wilking N. Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer. Br J Cancer 1992; 65: 927–9

    Article  PubMed  CAS  Google Scholar 

  130. Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 1989; 7: 1113–9

    PubMed  CAS  Google Scholar 

  131. Blarney RW, Jonat W, Kaufmann M, et al. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1992; 28A: 810–4

    Google Scholar 

  132. Santen RJ, Manni A, Harvey H, et al. Endocrine Treatment of breast cancer in women. Endocr Rev 1990; 11: 221–65

    Article  PubMed  CAS  Google Scholar 

  133. Blarney RW. Randomised trial comparing Zoladez with Nolvadex plus Zoladex in pre-menopausal advanced breast cancer. Proceedings of the International Symposium on GnRH Analogues in Cancer and Human Reproduction: 1993 Feb 25–28: Geneva. Geneva: The International Society of Gynecological Endocrinology, 1993: 67

    Google Scholar 

  134. Wilding G, Cehn M, Gelmann EP. LHRH agonists and human breast cancer cells. Nature 1987; 329: 770

    Article  PubMed  CAS  Google Scholar 

  135. Slotman BJ, Poels LG, Rao BR. A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment. Anticancer Res 1989; 9: 77–80

    PubMed  CAS  Google Scholar 

  136. McGowan L. Epidemiology of ovarian cancer. Oncology 1989; 46: 51–62

    Google Scholar 

  137. Emons G, Pahwa GS, Brack CH, et al. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1990; 25: 215–21

    Article  Google Scholar 

  138. Bruckner HW, Motwani BT. Treatment of advanced refractory ovarian carcinoma with gonadotrophin-releasing hormone analogue. Am J Obstet Gynecol 1989; 161: 1216–8

    PubMed  CAS  Google Scholar 

  139. Wigler N, Ron IG, Merimsky O, et al. A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Proceedings of the International Symposium on GnRH Analogues in Cancer and Human Reproduction: 1993 Feb 25–28: Geneva. Geneva: International Society of Gynecological Endocrinology, 1993: 72

    Google Scholar 

  140. Jager W. A randomised comparison of decapeptyl and tamoxifen as treatment of progressive ovarian cancer. Proceedings of the International Symposium on GnRH Analogues in Cancer and Human Reproduction: 1993 Feb 25–28: Geneva. Geneva: International Society of Gynecological Endocrinology, 1993: 72

    Google Scholar 

  141. Emons G, Schröder B, Ortmann O, et al. High efficacy binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993; 77: 1458–64

    Article  PubMed  CAS  Google Scholar 

  142. Srkalovic G, Wittliff JR, Schally AV. Detection and partial characterization of receptor for (D-Trp6) luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990; 50: 1841–6

    PubMed  CAS  Google Scholar 

  143. Gallagher CJ, Oliver RT, Oram DH, et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 1991; 98: 1037–41

    Article  PubMed  CAS  Google Scholar 

  144. Redding TW, Schally AR. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Aca Sci USA 1984; 81: 248–52

    Article  CAS  Google Scholar 

  145. Gonzalez-Barcena D, Rangel-Garcia NE, Perez-Sanchez PL, et al. Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas. Lancet 1986; 2: 154

    Article  PubMed  CAS  Google Scholar 

  146. Allegretti A, Lionetto R, Saccomanno S, et al. LH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Gruppo Ligure per lo Studio del Pancreas. Oncology 1993; 50: 77–80

    CAS  Google Scholar 

  147. Muse KN, Cetel NS, Lori A, et al. The premenstrual syndrome effects of ‘medical ovariectomy’. N Engl J Med 1984; 311: 1345–9

    Article  PubMed  CAS  Google Scholar 

  148. Bancroft J, Boyle H, Warner P, et al. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol 1987; 27: 171–82

    Article  CAS  Google Scholar 

  149. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67: 159

    Article  PubMed  CAS  Google Scholar 

  150. Slater JE, Raphael G, Cutler GB, et al. Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone agonist — a preliminary report. Obstet Gynecol 1987; 70: 542–6

    PubMed  CAS  Google Scholar 

  151. Andreyko JL, Jaffe RB. Use of a gonadotropin-releasing hormone agonist analogue for treatment of cyclic auditory dysfunction. Obstet Gynecol 1989; 74: 506–9

    PubMed  CAS  Google Scholar 

  152. Anderson KE, Spitz IM, Sassa S, et al. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 1984; 311: 643–5

    Article  PubMed  CAS  Google Scholar 

  153. Herzog AG. Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsia 1991; 32 Suppl. 6: S27–33

    Article  PubMed  Google Scholar 

  154. Blumenfeld Z, Enat R, Brandes JM, et al. Gonadotropin-releasing hormone analogues for dysfunctional bleeding in women after liver transplantation: a new application. Fertil Steril 1992; 57: 1121–3

    PubMed  CAS  Google Scholar 

  155. Steingold K, De Ziegler D, Cedars M, et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab 1987; 65: 773–8

    Article  PubMed  CAS  Google Scholar 

  156. Calogero AE, Macchi M, Montanini V, et al. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone. J Clin Endocrinol Metab 1987; 64: 980–5

    Article  PubMed  CAS  Google Scholar 

  157. de Ziegler D, Steingold K, Cedars M, et al. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. J Clin Endocrinol Metab 1989; 68: 1111–7

    Article  PubMed  Google Scholar 

  158. Waxman J, Rustin MHA, Perry L, et al. Acne conglobata responding to buserelin, a gonadotrophin-releasing hormone analogue. Br J Dermatol 1983; 109: 679–81

    Article  PubMed  CAS  Google Scholar 

  159. Faloia E, Filipponi S, Mancini V, et al. Treatment with gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J Endocrinol Invest 1993; 16: 675–7

    PubMed  CAS  Google Scholar 

  160. Barnes RB, Rosenfield RL, Burstein S, et al. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320: 559–65

    Article  PubMed  CAS  Google Scholar 

  161. Rittmaster RS, Thompson D. Effect of Leuprolide and dexa-methasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 1990; 70: 1096–102

    Article  PubMed  CAS  Google Scholar 

  162. Dunaif A, Green G, Futterweit W, et al. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 70: 699–704

    Article  PubMed  CAS  Google Scholar 

  163. Elkind-Hirsch K, Valdes CT, Malinak R. Insulin resistance in hyperandrogenic women treated with Lupron. Fertil Steril 1993; 60: 634–41

    PubMed  CAS  Google Scholar 

  164. Laufer MR, Rein MS. Treatment of abnormal uterine bleeding with gonadotropin-releasing hormone analogues. Clin Obstet Gynecol 1993; 36: 668–78

    Article  PubMed  CAS  Google Scholar 

  165. Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynecol 1984; 91: 913–6

    Article  CAS  Google Scholar 

  166. Gardner R, Shaw RW. LHRH analogues in the treatment of menorrhagia. In: Shaw RH, editor. Dysfunctional uterine bleeding. Carnforth: Parthenon Press, 1990; 149–50

    Google Scholar 

  167. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotropin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991; 98: 1155–9

    Article  PubMed  CAS  Google Scholar 

  168. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599–604

    Article  PubMed  CAS  Google Scholar 

  169. Matzkin H, Chen J, Lewysohn O, et al. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience. J Urol 1991; 145: 309–12

    PubMed  CAS  Google Scholar 

  170. Monsonego J, Destable MD, De Saint Florent G, et al. Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. Am J Obstet Gynecol 1991; 164: 1181–9

    PubMed  CAS  Google Scholar 

  171. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1: 1132–4

    Article  PubMed  CAS  Google Scholar 

  172. Johnson DH, Linde R, Hainworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on post-therapy fertility in male patients with lymphoma. Blood 1985; 65: 832–6

    PubMed  CAS  Google Scholar 

  173. Waxman JH, Smith AR, Wrigley PFM, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 1987; 19: 159–62

    Article  PubMed  CAS  Google Scholar 

  174. Kreuser ED, Hetzel WD, Hartmann R, et al. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990; 22: 494–8

    Article  PubMed  CAS  Google Scholar 

  175. Kreuser ED, Klingmuller D, Thiel E. The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation. Eur Urol 1993; 23: 157–63

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reproductive Endocrinology Center, University of Bologna, Bologna, Italy

    Marco Filicori

  2. Clinica Ostetrica e Ginecologica, Via Massarenti 13, 40138, Bologna, Italy

    Marco Filicori

Authors
  1. Marco Filicori
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03260132.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filicori, M. Gonadotrophin-Releasing Hormone Agonists. Drugs 48, 41–58 (1994). https://doi.org/10.2165/00003495-199448010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199448010-00005

Keywords

Search

Navigation